Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S (NOVO B)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
10/18/2017 10/19/2017 10/20/2017 10/23/2017 10/24/2017 Date
317.8(c) 319.5(c) 318.7(c) 319.3(c) 320.4 Last
5 575 854 5 160 743 2 528 184 2 489 178 1 209 808 Volume
+2.09% +0.53% -0.25% +0.19% +0.34% Change
More quotes
Financials ( DKK)
Sales 2017 113 B
EBIT 2017 49 131 M
Net income 2017 38 223 M
Finance 2017 18 527 M
Yield 2017 2,40%
Sales 2018 117 B
EBIT 2018 50 681 M
Net income 2018 40 001 M
Finance 2018 18 869 M
Yield 2018 2,57%
P/E ratio 2017 20,69
P/E ratio 2018 19,29
EV / Sales2017 5,38x
EV / Sales2018 5,19x
Capitalization 627 B
More Financials
Company
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products.It operates through the Diabetes and Obesity Care; and Biopharmaceuticals segments.The Diabetes and Obesity Care segment covers products for insulin; GLP-1 and... 
Sector
Pharmaceuticals
Calendar
11/01Earnings Release
More about the company
Surperformance© ratings of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVO NORDISK A/S
10/23 NOVO NORDISK A/S : - Share repurchase programme
10/23 NOVO NORDISK A/S : - Semaglutide receives positive 16-0 vote in favour of approv..
10/23 NOVO NORDISK A/S : New medicine for obesity hits Qatar market
10/20 NOVO NORDISK A/S : Addressing Diabetes in Nigeria
10/20 NOVO NORDISK A/S : Anemia Prevalence Promotes Growth Of Hematology Drugs Market
10/19 NOVO NORDISK A/S : Reports from Novo Nordisk Provide New Insights into Anterior ..
10/19 NOVO NORDISK A/S : Emanuel Mini moving up to Team Novo Nordisk pro squad
10/18 NOVO NORDISK A/S : Semaglutide receives positive 16-0 vote in favour of approval..
10/18 NOVO NORDISK A/S : - FDA posts briefing materials prior to Advisory Committee me..
10/17 NOVO NORDISK A/S : Emanuel Mini Moves Up to Team Novo Nordisk Pro Squad for the ..
More news
Sector news : Pharmaceuticals - NEC
07:50aDJNOVARTIS : 3Q Net Profit Rises as New Drugs Offset Generic Competition
10/23 European stocks hold firm as banks, Spanish shares fall
10/23 Smith & Nephew to buy Rotation Medical for up to $210 million
10/23DJEuropean Corporate Roundup for Monday
10/23DJDrug Makers Find 'Branded Generics' Are a Source for Growth
More sector news : Pharmaceuticals - NEC
Latest Tweets
10/20NNIT A/S: 8/2017 NNIT settles an arbitration with a public customer and chang.. 
10/19With FDA panel backing, Novo Nordisk prepares for semaglutide's potential lau.. 
10/19Novo Nordisk takes aim at Eli Lilly with U.S. backing of new diabetes drug
2
10/19Novo Nordisk takes aim at Eli Lilly with U.S. backing of new diabetes drug | .. 
10/19$NVO (+1.1% pre) Novo Nordisk receives positive 16-0 vote from FDA AdComm in ..
1
More tweets
Qtime:95
News from SeekingAlpha
10/20 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/19 Novo Nordisk (NVO) Presents At 22nd HR Shared Services 7 Outsourcing Summit -..
10/19 J&J : Unattractive
10/18 FDA Ad Com backs Novo's semaglutide for T2D; shares up 2% after hours
10/17 YOUR DAILY PHARMA SCOOP : Everybody's Gilead Problem, Halozyme's Further Progres..
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 299  DKK
Spread / Average Target -6,3%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S25.13%98 961
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.97%226 404
PFIZER12.13%216 886
ROCHE HOLDING LTD.0.77%207 116
MERCK AND COMPANY8.51%174 223